Articles related to BIOMARKERS

The interpretation of genomic sequencing data is complex. Not all tumors have alterations within therapeutically targetable or actionable genes, and not all alterations detected within a therapeutically actionable gene may confer sensitivity to genomic biomarker–linked therapies. ASCO’s expert panel provides a provisional opinion, giving guidance on using genomic sequencing to inform treatment selection for patients with metastatic or advanced solid tumors.

This study involved 566 men and women between the ages of 28 and 97 years, who were patients in a preventive cardiology practice. The PULS Cardiac Test measures multiple protein biomarkers, including hepatocyte growth factor, soluble Fas, and IL-16, and uses the results to calculate a five-year risk score for new ACS. All factors more than doubled their prior above the norm level. The 5-year ACS PULS risk score more than doubled as a result.

It was time for a change in neuroblastoma treatment planning, and this Original Report from the Journal of Clinical Oncology validates a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) while incorporating segmental chromosome aberrations (SCA) as an additional genomic biomarker.

From the pages of Blood Advances comes this Clinical Trials & Observations piece discussing the IDEAL trial. Backed by visual abstracts, tables, and charts supporting the data, the article explores two key points in augmenting chemotherapy efficacy: caloric restriction and using insulin and adiponectin as potential biomarkers of B-ALL chemosensitivity.

In this MedPage Today interview with Jason Karlawish, MD, co-director of the Penn Memory Center at the University of Pennsylvania in Philadelphia and author of the new book, The Problem of Alzheimer’s: How Science, Culture, and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It, the  biomarker “revolution” is discussed, along with the discovery of the idea of mild cognitive impairment.